Technical Analysis for GTHX - G1 Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 14.4 -4.51% -0.68
GTHX closed down 4.51 percent on Friday, March 22, 2019, on 1.59 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
3 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical GTHX trend table...

Date Alert Name Type % Chg
Mar 22 New 52 Week Closing Low Bearish 0.00%
Mar 22 New 52 Week Low Weakness 0.00%
Mar 22 Wide Bands Range Expansion 0.00%
Mar 22 Down 3 Days in a Row Weakness 0.00%
Mar 22 Oversold Stochastic Weakness 0.00%
Mar 21 New 52 Week Closing Low Bearish -4.51%
Mar 21 Doji - Bullish? Reversal -4.51%
Mar 21 New 52 Week Low Weakness -4.51%
Mar 21 Wide Bands Range Expansion -4.51%
Mar 21 Oversold Stochastic Weakness -4.51%

Older signals for GTHX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:
Profile
G1 Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.
Biopharmaceutical Cancer Drugs Treatment Of Cancer Breast Cancer Hormones Astrazeneca Protein Kinase Inhibitors Treatment Of Breast Cancer Her2/Neu Antiestrogens
Is GTHX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Mar 21 The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering
Mar 4 G1 Therapeutics to Present at Cowen and Company 39th Annual Healthcare Conference
Mar 2 G1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q4 2018 Results - Earnings Call Transcript
Mar 1 Edited Transcript of GTHX.O earnings conference call or presentation 28-Feb-19 9:30pm GMT
Feb 28 G1 Therapeutics, Inc. (GTHX) Q4 2018 Earnings Conference Call Transcript
Feb 28 G1 Therapeutics misses by $0.07
Feb 28 G1 Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results
Feb 28 The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems
Feb 27 G1 Therapeutics to Host Investor Day 2019 on March 6, 2019
Feb 21 G1 Therapeutics to Report Fourth Quarter and Full-Year 2018 Financial Results on February 28, 2019
See more GTHX news...
Indicators
Indicator Value
52 Week High 69.57
52 Week Low 14.39
Average Volume 283,509
200-Day Moving Average 38.3569
50-Day Moving Average 19.262
20-Day Moving Average 17.4595
10-Day Moving Average 15.857
Average True Range 1.1849
ADX 33.58
+DI 10.3543
-DI 31.5403
Chandelier Exit (Long, 3 ATRs ) 18.0553
Chandelier Exit (Short, 3 ATRs ) 17.9447
Upper Bollinger Band 21.385
Lower Bollinger Band 13.534
Percent B (%b) 0.11
BandWidth 44.966923
MACD Line -1.4517
MACD Signal Line -1.2438
MACD Histogram -0.2079
Fundamentals Value
Market Cap 407.3 Million
Num Shares 28.3 Million
EPS -11.02
Price-to-Earnings (P/E) Ratio -1.31
Price-to-Sales 0.00
Price-to-Book 4.87
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.83
Resistance 3 (R3) 15.98 15.66 15.59
Resistance 2 (R2) 15.66 15.30 15.58 15.51
Resistance 1 (R1) 15.03 15.07 14.87 14.88 15.43
Pivot Point 14.71 14.71 14.63 14.63 14.71
Support 1 (S1) 14.08 14.35 13.92 13.93 13.37
Support 2 (S2) 13.76 14.12 13.68 13.29
Support 3 (S3) 13.13 13.76 13.21
Support 4 (S4) 12.98